Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.90
+0.09 (0.92%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Zevra Therapeutics Employees
Zevra Therapeutics had 61 employees as of December 31, 2025. The number of employees increased by 2 or 3.39% compared to the previous year.
Employees
61
Change (1Y)
2
Growth (1Y)
3.39%
Revenue / Employee
$1,745,410
Profits / Employee
$1,271,885
Market Cap
585.24M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| CorMedix | 191 |
| Rigel Pharmaceuticals | 174 |
| Kyverna Therapeutics | 130 |
| Ocugen | 116 |
| Aclaris Therapeutics | 73 |
| Prothena Corporation | 67 |
| AgomAb Therapeutics NV | 58 |
ZVRA News
- 5 weeks ago - Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - Zevra Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call - GlobeNewsWire
- 2 months ago - Zevra Therapeutics to Present at the Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp